Distribution and effects of neuropeptide Y, vasoactive intestinal peptide, substance P, and calcitonin gene-related peptide in human middle meningeal arteries: comparison with cerebral and temporal arteries.
A sparse to moderate supply of nerve fibers containing neuropeptide Y-like immunoreactivity (NPY-LI), vasoactive intestinal polypeptide (VIP-LI), substance P (SP-LI), and calcitonin gene-related peptide (CGRP-LI) was demonstrated in the walls of human middle meningeal arteries. Comparison with similar studies on human cerebral and temporal arteries indicated a similar distribution and density. The immunoreactive material in all three arterial regions was characterized by reversed-phase high pressure liquid chromatography (HPLC) and radioimmunoassay (RIA). The major peak of NPY-LI, VIP-LI, SP-LI, and CGRP-LI in each extract eluted approximately with the same elution volume as that of the corresponding synthetic analogues. The concentration of NPY in the middle meningeal arteries was lower as compared to the temporal arteries. Low concentrations of SP-LI and CGRP-LI were found in the middle meningeal arteries as compared to the cerebral arteries. In isolated ring segments of human middle meningeal and cerebral arteries, NPY caused vasoconstriction but did not potentiate the contractile response of noradrenaline. In the temporal artery, NPY did not induce contraction but potentiated the vasoconstrictor response to noradrenaline. Vasoactive intestinal polypeptide, peptide histidine methionine-27, SP, neurokinin A, and CGRP relaxed all three types of cephalic arteries. The peptide effects were not antagonized by propranolol, atropine, or cimetidine. Comparison of the responses to VIP and SP of vessels from the different regions showed a similar pattern of reactivity. The response to SP was slightly (p less than 0.05) more potent, whereas the responses to CGRP were less potent in the middle meningeal as compared to that in cerebral (p less than 0.005) vessels.
Jansen
I
I
Department of Experimental Research, Malmö General Hospital, Sweden.
Uddman
R
R
Ekman
R
R
Olesen
J
J
Ottosson
A
A
Edvinsson
L
L
D000109:Acetylcholine / Q000494:pharmacology; D000368:Aged; D015740:Calcitonin Gene-Related Peptide / Q000302:isolation & purification / Q000494:pharmacology; D002941:Circle of Willis / Q000737:chemistry / Q000187:drug effects / Q000502:physiology; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007150:Immunohistochemistry; D008576:Meningeal Arteries / Q000737:chemistry / Q000187:drug effects / Q000502:physiology*; D008875:Middle Aged; D009119:Muscle Contraction / Q000187:drug effects; D009478:Neuropeptide Y / Q000302:isolation & purification / Q000494:pharmacology; D009479:Neuropeptides / Q000302:isolation & purification* / Q000494:pharmacology*; D013373:Substance P / Q000302:isolation & purification / Q000494:pharmacology; D013699:Temporal Arteries / Q000737:chemistry / Q000187:drug effects / Q000502:physiology; D014660:Vasoactive Intestinal Peptide / Q000302:isolation & purification / Q000494:pharmacology; D014661:Vasoconstriction / Q000187:drug effects / Q000502:physiology*; D014665:Vasodilator Agents / Q000494:pharmacology
D009478:Neuropeptide Y; D009479:Neuropeptides; D014665:Vasodilator Agents; D013373:Substance P; D014660:Vasoactive Intestinal Peptide; D015740:Calcitonin Gene-Related Peptide; D000109:Acetylcholine